Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.
Sunmax Biotechnology Co Ltd (4728) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.111x
Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has a cash flow conversion efficiency ratio of 0.111x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$160.84 Million) by net assets (NT$1.44 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sunmax Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sunmax Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
0.071x |
|
ASNFF
PINK:ASNFF
|
N/A |
|
Sinopec Oilfield Service Corporation
PINK:YZCFF
|
0.052x |
|
Beijing Jingpin Tezhuang Technology Co. Ltd. A
SHG:688084
|
N/A |
|
FORTERRA PLC LS -01
F:F0T
|
N/A |
|
Südzucker AG
PINK:SUEZF
|
-0.001x |
|
Norwegian Energy Co. ASA
LSE:0HTF
|
0.183x |
|
Synopex Inc
KQ:025320
|
0.071x |
Annual Cash Flow Conversion Efficiency for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Sunmax Biotechnology Co Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.51 Billion | NT$397.37 Million | 0.263x | -55.86% |
| 2023-12-31 | NT$1.43 Billion | NT$848.56 Million | 0.595x | +129.93% |
| 2022-12-31 | NT$1.33 Billion | NT$342.97 Million | 0.259x | +8.88% |
| 2021-12-31 | NT$1.02 Billion | NT$243.28 Million | 0.238x | -45.41% |
| 2020-12-31 | NT$888.84 Million | NT$386.97 Million | 0.435x | +1.78% |
| 2019-12-31 | NT$676.83 Million | NT$289.51 Million | 0.428x | +174.90% |
| 2018-12-31 | NT$648.01 Million | NT$100.83 Million | 0.156x | +140.26% |
| 2017-12-31 | NT$572.70 Million | NT$37.09 Million | 0.065x | +116.86% |
| 2016-12-31 | NT$555.29 Million | NT$16.58 Million | 0.030x | +172.98% |
| 2015-12-31 | NT$558.24 Million | NT$-22.84 Million | -0.041x | -- |